Zai Lab Q2 product rev $68.9M (+45% YoY); VYVGART approved in China; net loss $120.9M

Zai Lab Ltd

2023-Q2 EPS reported -$0.18 revenue$131,661,000

Product revenue $68.9M, up 45% YoY (53% constant currency); driven by ZEJULA $43.0M, Optune $13.7M.
Net loss $120.9M ($0.13 loss per ADS) vs $137.9M loss a year ago; R&D spend $76.7M, SG&A $67.9M.
Cash $876.4M as of June 30, 2023; down from $931.4M at March 31, 2023.
NMPA approved VYVGART (efgartigimod) for gMG; launch preparation underway; NRDL listing eligible for 2024.
Promoted Yajing Chen to CFO effective July 7, 2023; targeting corporate profitability by end of 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zai Lab Ltd reported the second quarter of 2023 results: revenue $68.9 million.

Period: the second quarter of 2023
Revenue: $68.9 million
Result: reported results

Exact text from the filing

Total product revenue of $68.9 million for the second quarter of 2023

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Zai Lab Ltd filing history →

Source: SEC EDGAR

accession 0001628280-23-027767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.